SpIntellx

Issuance of U.S. Patent Quantifying Intratumor Spatial Heterogeneity

Share This Post

The newly issued U.S. Patent No. 10,755,138 covers the application of point-wise mutual information maps to quantify spatial intratumor heterogeneity and identify diagnostic regions of interest in tissue samples. This patent has been exclusively licensed to SpIntellx, Inc. from the University of Pittsburgh and further adds to the strong and growing IP portfolio of SpIntellx around spatial analytics, xAI and spatial network biology.

Read more…

Back to NEWS

More To Explore

SpIntellx at AACR 2022

SpIntellx is ushering a new era of unbiased spatial analytics and explainable AI in precision pathology at AACR 2022 SpIntellx announces that it will attend

April 5, 2022

Thank you USCAP 2022 attendees

Thank you to everyone who visited our booth during the 2022 United States & Canadian Academy of Pathology (USCAP) 111th Annual Meeting in Los Angeles.

April 1, 2022

Subscribe to our Newsletter

* indicates required

S. Chakra Chennubhotla, PhD

PRESIDENT, CO-FOUNDER, &
CHIEF TECHNOLOGY OFFICER

Linkedin-in

Chakra earned his PhD from the Department of Computer Science at the University of Toronto specializing in computer vision, machine learning and AI. Chakra was tenured Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh.

Chakra co-founded SpIntellx to actualize the translational potential of these Pitt IP-fueled platforms. Chakra’s experience encompasses years in both industry and academia. He was the lead PI on several National Institutes of Health and National Science Foundation grants covering broad areas of bioimaging, molecular biophysics, computational and systems biology, and spatial intratumor heterogeneity. He holds several patents and has published extensively, appearing in Science Translational Medicine and Nature Communications, among other prominent journals.

Submit your Resume

Download Whitepaper

Download Whitepaper

B. Dusty Majumdar, PhD

CHIEF EXECUTIVE OFFICER

Linkedin-in

B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Joe Camaratta

Sr. VP Business Development

Linkedin-in

Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.

Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations

D. Lansing Taylor, PhD

EXECUTIVE CHAIRMAN & CO-FOUNDER

Linkedin-in

Dr. Taylor is currently the Director of the University of Pittsburgh Drug Discovery Institute managing the collaborative programs involving clinicians, biomedical scientists, chemists, engineers and systems biologists at Pitt, Carnegie Mellon University, the University of Pittsburgh Medical Center, as well as external collaborators from academia, federal agencies and industry.

Lans was Co-Founder and CEO of Cellomics Inc., which developed and commercialized High Content Screening (HCS) that permitted single cell quantitation of multiplexed fluorescence biomarkers in arrays of cells and tissues. In addition to Cellomics, Dr. Taylor co-founded several other biotech companies, such as Biological Detection Systems, Inc. and Cernostics, Inc., and is an expert in multiplexed fluorescence and biomarker imaging.